Discontinuing Prophylactic Transfusions Used to Prevent Stroke in Sickle Cell Disease
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Prophylactic transfusion prevents strokes in children with sickle cell anemia who have abnormalities on transcranial Doppler ultrasonographic examination. However, it is not known how long transfusion should be continued in these children. METHODS: We studied children with sickle cell disease who had a high risk of stroke on the basis of a transcranial Doppler screening examination and who had received transfusions for 30 months or longer, during which time the Doppler readings became normal. The children were randomly assigned to continued transfusion or no continued transfusion. Children with severe stenotic lesions on cerebral magnetic resonance angiography were excluded. The composite primary end point was stroke or reversion to a result on Doppler examination indicative of a high risk of stroke. RESULTS: The study was stopped after 79 children of a planned enrollment of 100 underwent randomization. Among the 41 children in the transfusion-halted group, high-risk Doppler results developed in 14 and stroke in 2 others within a mean (+/-SD) of 4.5+/-2.6 months (range, 2.1 to 10.1) of the last transfusion. Neither of these events of the composite end point occurred in the 38 children who continued to receive transfusions. The average of the last two transcranial Doppler results before transfusion was started was the only predictor of the composite end point (P=0.05). CONCLUSIONS: Discontinuation of transfusion for the prevention of stroke in children with sickle cell disease results in a high rate of reversion to abnormal blood-flow velocities on Doppler studies and stroke. (ClinicalTrials.gov number, NCT00006182.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the approximately 22% of children who did not achieve normalization of transcranial Doppler velocity in spite of optimal transfusion in the trial were also protected from stroke (162).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [162]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Adams, R. J., McKie, V. C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., Gallagher, D., Kutlar, A., Nichols, F. T., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807023390102 · Cited by 1,866
Cerebrovascular accidents in sickle cell disease: rates and risk factors.
(1998) · PubMed · doi:10.1182/blood.v91.1.288 · Cited by 1,694
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Dams, R. O. J. A., Ie, V. I. C. M. C. K., Su, L. E. H., Iles, B. E. F., Ichinsky, E. L. V., Egelow, C. H. P., Bboud, M. I. A., Allagher, D. I. G., Utlar, K., Ichols, F. E. T. N., et al. (2015) · Cited by 1,338
Steinberg, M. H., Barton, F., Castro, O., Pegelow, C. H., Ballas, S. K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1645 · Cited by 931
Goldstein, L. B., Adams, R., Becker, K., Furberg, C. D., Gorelick, P. B., Hademenos, G., Hill, M., Howard, G., Howard, V. J., Jacobs, B., et al. (2001) · Stroke · doi:10.1161/01.str.32.1.280 · Cited by 905
The Use of Transcranial Ultrasonography to Predict Stroke in Sickle Cell Disease
Adams, R., McKie, V., Nichols, F., Carl, E., Zhang, D.-L., McKie, K., Figueroa, R., Litaker, M., Thompson, W., & Hess, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202273260905 · Cited by 658
Research works printed but not linked: 2
- Ohene-Frempong K, 1998, Blood, 91, 288
- Walters MC, 2000, Blood, 95, 1918
Cited by
Items 101–200 of 665
Deferasirox (Exjade®) for the Treatment of Iron Overload
Cappellini, M. D., & Taher, A. T. (2009) · Acta Haematologica · doi:10.1159/000243801 · Cited by 68
Crosby, L. E., Quinn, C. T., & Kalinyak, K. A. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0197-1 · Cited by 67
Evensen, C., Treadwell, M. J., Keller, S., Levine, R. E., Hassell, K. L., Werner, E. M., & Smith, W. R. (2016) · Medicine · doi:10.1097/md.0000000000004528 · Cited by 66
Management of Children With Sickle Cell Disease: A Comprehensive Review of the Literature
Kavanagh, P. L., Sprinz, P. G., Vinci, S. R., Bauchner, H., & Wang, C.-H. J. (2011) · PEDIATRICS · doi:10.1542/peds.2010-3686 · Cited by 66
Pediatric sickle cell disease: past successes and future challenges
Meier, E. R., & Rampersad, A. G. (2016) · Pediatric Research · doi:10.1038/pr.2016.204 · Cited by 65
Hankins, J. S., Fortner, G., McCarville, M. B., Smeltzer, M. P., Wang, W. C., Li, C., & Ware, R. E. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07167.x · Cited by 65
Treatment of childhood arterial ischemic stroke
Bernard, T. J., Goldenberg, N. A., Armstrong, J., Amlie‐Lefond, C., & Fullerton, H. J. (2008) · Annals of Neurology · doi:10.1002/ana.21406 · Cited by 64
Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease
Osunkwo, I., Manwani, D. G., & Kanter, J. (2020) · Therapeutic Advances in Hematology · doi:10.1177/2040620720955000 · Cited by 64
Therapy Insight: stroke risk and its management in patients with sickle cell disease
Kirkham, F. J. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0495 · Cited by 64
Management of sickle cell disease
de Montalembert, M. (2008) · BMJ · doi:10.1136/bmj.a1397 · Cited by 63
Current Management of Sickle Cell Anemia
McGann, P. T., Nero, A. C., & Ware, R. E. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011817 · Cited by 63
Wood, J. C., Cohen, A. R., Pressel, S., Aygün, B., Imran, H., Luchtman‐Jones, L., Thompson, A. A., Fuh, B., Schultz, W. H., Davis, B. R., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13791 · Cited by 62
Self-citationSilva, G. S., Vicari, P., Figueiredo, M. S., Carrete, H., Idagawa, M. H., & Massaro, A. R. (2009) · Stroke · doi:10.1161/strokeaha.108.537415 · Cited by 62
Biller, E., Zhao, Y., Berg, M. P., Boggio, L. N., Capocelli, K. E., Fang, D. C., Koepsell, S. A., Aplenc, L. M., Pham, H. P., Treml, A., et al. (2018) · Transfusion · doi:10.1111/trf.14806 · Cited by 62
Troncs supra-aortiques et écho-Doppler transcrânien
(2015) · Elsevier eBooks · doi:10.1016/b978-2-294-71947-9.00002-7 · Cited by 62
Therapeutic apheresis: history, clinical application, and lingering uncertainties
McLeod, B. C. (2009) · Transfusion · doi:10.1111/j.1537-2995.2009.02505.x · Cited by 62
Maintaining adequate donations and a sustainable blood supply: Lessons learned
Gammon, R. R., Rosenbaum, L., Cooke, R. K., Friedman, M. T., Rockwood, L., Nichols, T., & Vossoughi, S. R. (2020) · Transfusion · doi:10.1111/trf.16145 · Cited by 61
DNA-based methods in the immunohematology reference laboratory
Reid, M. E., & Denomme, G. A. (2011) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2010.12.011 · Cited by 61
Genomic analyses of RH alleles to improve transfusion therapy in patients with sickle cell disease
Reid, M. E., Hipsky, C. H., Hue‐Roye, K., & Hoppe, C. C. (2013) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2013.11.003 · Cited by 61
Fortin, P. M., Hopewell, S., & Estcourt, L. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012082.pub2 · Cited by 61
Preventing Stroke in Sickle Cell Anemia
Platt, O. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmp058274 · Cited by 60
Consenso brasileiro em transplante de células-tronco hematopoéticas: comitê de hemoglobinopatias
Simões, B. P., Pieroni, F., Barros, G. M. N., Machado, C. L., Cançado, R. D., Salvino, M. A., Ângulo, I. L., & Voltarelli, J. C. (2010) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1590/s1516-84842010005000020 · Cited by 60
McLeod, C., Fleeman, N., Kirkham, J. J., Bagust, A., Boland, A., Chu, P., Dickson, R., Dundar, Y., Greenhalgh, J., Modell, B., et al. (2009) · Health Technology Assessment · doi:10.3310/hta13010 · Cited by 59
Russo, G. M., Franceschi, L. D., Colombatti, R., Rigano, P., Perrotta, S., Voi, V., Palazzi, G., Fidone, C., Quota, A., Graziadei, G., et al. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1099-0 · Cited by 59
Ischemic stroke in children and young adults with sickle cell disease in the post‐STOP era
Kwiatkowski, J. L., Voeks, J. H., Kanter, J., Fullerton, H. J., Debenham, E., Brown, L., Adams, R. J., & for the Post‐STOP Study Group (2019) · American Journal of Hematology · doi:10.1002/ajh.25635 · Cited by 59
Hepatic Iron Overload in Children With Sickle Cell Anemia on Chronic Transfusion Therapy
Brown, K. S., Subramony, C., May, W., MEGASON, G. C., Liu, H., Bishop, P. R., Walker, T., & Nowicki, M. J. (2009) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e3181a1c143 · Cited by 58
Sarode, R., Matevosyan, K., Rogers, Z. R., Burner, J. D., & Rutherford, C. (2011) · Journal of Clinical Apheresis · doi:10.1002/jca.20294 · Cited by 58
Kalff, A., Dowsing, C., & Grigg, A. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08150.x · Cited by 57
Indications and complications of transfusions in sickle cell disease
Smith‐Whitley, K., & Thompson, A. A. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24179 · Cited by 57
Neuroimaging findings in sickle cell disease
Thust, S. C., Burke, C., & Siddiqui, A. (2014) · British Journal of Radiology · doi:10.1259/bjr.20130699 · Cited by 57
Endothelial function and arterial stiffness in sickle-thalassemia patients
Aessopos, A., Farmakis, D., Tsironi, M., Diamanti-Kandarakis, E., Matzourani, M., Fragodimiri, C., Hatziliami, A., & Karagiorga, M. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.04.015 · Cited by 56
Advances in the Diagnosis and Treatment of Pediatric Arterial Ischemic Stroke
Sun, L. R., & Lynch, J. K. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01373-5 · Cited by 56
Opportunities to improve outcomes in sickle cell disease.
Mehta, S. R., Afenyi‐Annan, A., Byrns, P. J., & Lottenberg, R. (2006) · PubMed · Cited by 56
Prospects for primary stroke prevention in children with sickle cell anaemia
Jordan, L. C., Casella, J. F., & DeBaun, M. R. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.09005.x · Cited by 55
Sickle Cell Disease: An Opportunity for Palliative Care Across the Life Span
Wilkie, D. J., Johnson, B., Mack, A. K., Labotka, R., & Molokie, R. E. (2010) · Nursing Clinics of North America · doi:10.1016/j.cnur.2010.03.003 · Cited by 55
Fasano, R. M., Leong, T. L., Kaushal, M., Sagiv, E., Luban, N. L. C., & Meier, E. R. (2016) · Transfusion · doi:10.1111/trf.13558 · Cited by 55
Red Blood Cells: Exchange, Transfuse, or Deplete
Stüssi, G., Buser, A. S., & Holbro, A. (2019) · Transfusion Medicine and Hemotherapy · doi:10.1159/000504144 · Cited by 54
Brousse, V. A. M., Hertz‐Pannier, L., Consigny, Y., Bresson, J., Girot, R., Mirre, E., Lenoir, G., & de Montalembert, M. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0670-x · Cited by 54
Ali, S. B., MooSang, M., King, L., Knight‐Madden, J., & Reid, M. (2011) · American Journal of Hematology · doi:10.1002/ajh.22142 · Cited by 50
Red cell exchange: special focus on sickle cell disease
Kim, H. C. (2014) · Hematology · doi:10.1182/asheducation-2014.1.450 · Cited by 53
Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease
Locatelli, F., & Pagliara, D. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24177 · Cited by 53
Kuo, K. H. M., Ward, R. A., Kaya, B., Howard, J., & Telfer, P. T. (2015) · British Journal of Haematology · doi:10.1111/bjh.13294 · Cited by 53
Polymeric nanocarriers for the treatment of systemic iron overload
Hamilton, J. L., & Kizhakkedathu, J. N. (2015) · Molecular and Cellular Therapies · doi:10.1186/s40591-015-0039-1 · Cited by 53
Colombatti, R., Perrotta, S., Samperi, P., Casale, M., Masera, N., Palazzi, G., Sainati, L., & Russo, G. M. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-169 · Cited by 53
Molecular biology of the Rh system: clinical considerations for transfusion in sickle cell disease
Chou, S. T., & Westhoff, C. M. (2009) · Hematology · doi:10.1182/asheducation-2009.1.178 · Cited by 52
Cerebral vasculopathy in children with sickle cell anemia
Fasano, R. M., Meier, E. R., & Hulbert, M. L. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.08.007 · Cited by 51
Measuring success: utility of biomarkers in sickle cell disease clinical trials and care
Kalpatthi, R. V., & Novelli, E. M. (2018) · Hematology · doi:10.1182/asheducation-2018.1.482 · Cited by 51
Griessenauer, C. J., Lebensburger, J. D., Chua, M. H. J., Fisher, W. S., Hilliard, L., Bemrich‐Stolz, C. J., Howard, T. H., & Johnston, J. M. (2015) · Journal of Neurosurgery Pediatrics · doi:10.3171/2014.12.peds14522 · Cited by 51
Brazauskas, R., Scigliuolo, G. M., Wang, H.-L., Cappelli, B., Ruggeri, A., Fitzhugh, C. D., Hankins, J. S., Kanter, J., Meerpohl, J. J., Panepinto, J. A., et al. (2020) · Blood · doi:10.1182/blood.2020005687 · Cited by 50
How I manage cerebral vasculopathy in children with sickle cell disease
Brousse, V. A. M., Kossorotoff, M., & de Montalembert, M. (2015) · British Journal of Haematology · doi:10.1111/bjh.13477 · Cited by 50
Kwiatkowski, J. L., Yim, E., Miller, S., Adams, R. J., & for the STOP 2 Study Investigators (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.22951 · Cited by 49
“This theory is supported by a recent publication that showed that only three of nine children receiving transfusions for abnormal TCD showed progression of magnetic resonance imaging (MRI) and/or MRA findings and two of these three had MRI/A abnormalities prior to starting transfusions [10].”
InfluentialBlood transfusion for preventing primary and secondary stroke in people with sickle cell disease
Estcourt, L. J., Kohli, R., Hopewell, S., Trivella, M., & Wang, W. C. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003146.pub4 · Cited by 49
Cherry, M. G., Greenhalgh, J., Osipenko, L., Venkatachalam, M., Boland, A., Dundar, Y., Marsh, K., Dickson, R., & Rees, D. C. (2012) · Health Technology Assessment · doi:10.3310/hta16430 · Cited by 49
Drépanocytose et atteinte vasculaire cérébrale chez l’enfant
Kossorotoff, M., Grévent, D., & de Montalembert, M. (2014) · Archives de Pédiatrie · doi:10.1016/j.arcped.2014.01.005 · Cited by 48
Glaros, A. K., Razvi, R., Shah, N., & Zaidi, A. U. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211001136 · Cited by 48
Prevention and Management of Stroke in Sickle Cell Anemia
Platt, O. S. (2006) · Hematology · doi:10.1182/asheducation-2006.1.54 · Cited by 48
Hankins, J. S., Smeltzer, M. P., McCarville, M. B., Aygün, B., Hillenbrand, C. M., Ware, R. E., & Onciu, M. M. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01449.x · Cited by 48
How I manage red cell transfusions in patients with sickle cell disease
Rees, D. C., Robinson, S. E., & Howard, J. (2018) · British Journal of Haematology · doi:10.1111/bjh.15115 · Cited by 47
Management of Sickle Cell Disease Complications Beyond Acute Chest Syndrome
Ogu, U. O., Badamosi, N. U., Camacho, P. E., Freire, A. X., & Adams-Graves, P. E. (2021) · Journal of Blood Medicine · doi:10.2147/jbm.s291394 · Cited by 47
(2012) · Journal of Ultrasound in Medicine · doi:10.7863/jum.2012.31.9.1489 · Cited by 47
Sickle cell disease in children: an update of the evidence in low- and middle-income settings
Odame, I. (2022) · Archives of Disease in Childhood · doi:10.1136/archdischild-2021-323633 · Cited by 46
The role of molecular immunohematology in sickle cell disease
Chou, S. T., & Westhoff, C. M. (2011) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2010.12.014 · Cited by 46
Kirkham, F. J., Lerner, N. B., Noetzel, M. J., DeBaun, M. R., Datta, A. K., Rees, D. C., & Adams, R. J. (2006) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2005.10.017 · Cited by 46
Protective effect of HLA-DQB1 alleles against alloimmunization in patients with sickle cell disease
Tatari-Calderone, Z., Gordish‐Dressman, H., Fasano, R. M., Riggs, M., Fortier, C., Campbell, A., Charron, D. J., Gordeuk, V. R., Luban, N. L. C., Vukmanović, S., et al. (2015) · Human Immunology · doi:10.1016/j.humimm.2015.10.010 · Cited by 45
Hyacinth, H. I., Adams, R. J., Voeks, J. H., Hibbert, J. M., & Gee, B. E. (2013) · American Journal of Hematology · doi:10.1002/ajh.23586 · Cited by 45
Badawy, S. M., Liem, R. I., Rigsby, C. K., Labotka, R., de Freitas, R. A., & Thompson, A. A. (2016) · British Journal of Haematology · doi:10.1111/bjh.14277 · Cited by 45
Hoppe, C. C., & Neumayr, L. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.01.014 · Cited by 44
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease
Estcourt, L. J., Fortin, P. M., Hopewell, S., Trivella, M., & Wang, W. C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003146.pub3 · Cited by 37
Aygün, B., Wruck, L. M., Schultz, W. H., Mueller, B. U., Brown, C., Luchtman‐Jones, L., Jackson, S. M., Iyer, R. V., Rogers, Z. R., Sarnaik, S. A., et al. (2011) · American Journal of Hematology · doi:10.1002/ajh.23105 · Cited by 43
Zimrin, A. B., & Hess, J. R. (2007) · Transfusion · doi:10.1111/j.1537-2995.2007.01225.x · Cited by 42
Guilliams, K. P., Fields, M. E., & Dowling, M. M. (2019) · Stroke · doi:10.1161/strokeaha.118.020482 · Cited by 42
de Montalembert, M., Ferster, A., Colombatti, R., Rees, D. C., Gulbis, B., & on behalf of the European Network for Rare and Congenital Anaemias (2010) · American Journal of Hematology · doi:10.1002/ajh.21865 · Cited by 42
Central Nervous System Complications of Sickle Cell Disease in Children: An Overview
Wang, W. C. (2006) · Child Neuropsychology · doi:10.1080/09297040600788136 · Cited by 42
Blood bank management of sickle cell patients at comprehensive sickle cell centers
Afenyi‐Annan, A., Willis, M. S., Konrad, T. R., & Lottenberg, R. (2007) · Transfusion · doi:10.1111/j.1537-2995.2007.01434.x · Cited by 42
How I treat sickle cell disease with gene therapy
Sharma, A. (2024) · Blood · doi:10.1182/blood.2024024519 · Cited by 40
Vascular complications of sickle cell disease
Usmani, A., & Machado, R. F. (2018) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-189008 · Cited by 40
Mirre, E., Brousse, V. A. M., Berteloot, L., Lambot, K., Verlhac, S., Boulat, C., Dumont, M., Lenoir, G., & de Montalembert, M. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01379.x · Cited by 40
Estcourt, L. J., Fortin, P. M., Hopewell, S., & Trivella, M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012082 · Cited by 39
Novel insights in the management of sickle cell disease in childhood
Iughetti, L., Bigi, E., & Venturelli, D. (2016) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v5.i1.25 · Cited by 39
Mazumdar, M., Heeney, M. M., Sox, C. M., & Lieu, T. A. (2007) · PEDIATRICS · doi:10.1542/peds.2006-2002 · Cited by 39
Haematological Diseases in the Tropics
Thachil, J. V., Owusu‐Ofori, S., & Bates, I. (2013) · Elsevier eBooks · doi:10.1016/b978-0-7020-5101-2.00066-2 · Cited by 38
Sarode, R., Ballas, S. K., Garcia, A., Kim, H. C., King, K. E., Sachais, B. S., & Williams, L. A. (2016) · Journal of Clinical Apheresis · doi:10.1002/jca.21511 · Cited by 38
Frequently asked questions by hospitalists managing pain in adults with sickle cell disease
Smith, W. R., Jordan, L. B., & Hassell, K. L. (2011) · Journal of Hospital Medicine · doi:10.1002/jhm.933 · Cited by 37
Tsivgoulis, G. K., & Alexandrov, A. V. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000374 · Cited by 37
Pharmacological management of sickle cell disease.
Ndefo, U. A., Eaton, A., Nguyen, H. T., & Chiobi, T. L. (2008) · PubMed · Cited by 37
Pediatric Stroke: Past, Present and Future
Friedman, N. (2009) · Advances in Pediatrics · doi:10.1016/j.yapd.2009.08.003 · Cited by 36
Transcranial Doppler ultrasonography: a diagnostic tool of increasing utility
Kincaid, M. S. (2008) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e32830edc0b · Cited by 36
Interventions for preventing silent cerebral infarcts in people with sickle cell disease
Estcourt, L. J., Fortin, P. M., Hopewell, S., Trivella, M., Doree, C. J., & Abboud, M. R. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012389.pub2 · Cited by 36
Viprakasit, V., Gattermann, N., Lee, J. W., Porter, J. B., Taher, A. T., Habr, D., Martin, N., Domokos, G., & Cappellini, M. D. (2013) · Europe PMC (PubMed Central) · doi:10.2450/2012.0012-12 · Cited by 36
Relevance of alloimmunization in haemolytic transfusion reaction in sickle cell disease
Pirenne, F. (2012) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2012.03.004 · Cited by 35
Long-term red blood cell exchange in children with sickle cell disease: Manual or automatic?
Duclos, C., Merlin, É., Paillard, C., Thuret, I., Deméocq, F., Michel, G., & Kanold, J. (2012) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2012.09.002 · Cited by 34
Brambilla, D. J., Miller, S. T., & Adams, R. J. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21142 · Cited by 34
Concise Review: Production of Cultured Red Blood Cells from Stem Cells
Bouhassira, E. E. (2012) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0097 · Cited by 34
Overview of molecular methods in immunohematology
Reid, M. E. (2007) · Transfusion · doi:10.1111/j.1537-2995.2007.01304.x · Cited by 34
Kelly, S., Quirolo, K. C., Marsh, A., Neumayr, L., Garcia, A., & Custer, B. (2016) · Transfusion · doi:10.1111/trf.13800 · Cited by 34
The trials and hopes for drug development in sickle cell disease
Ataga, K. I., & Stocker, J. W. (2015) · British Journal of Haematology · doi:10.1111/bjh.13548 · Cited by 33
Meremikwu, M. M., & Okomo, U. (2003) · Europe PMC (PubMed Central) · Cited by 33
Yang, W., Xu, R., Porras, J. L., Takemoto, C. M., Khalid, S. I., Garzón-Muvdi, T., Caplan, J. M., Colby, G. P., Coon, A. L., Tamargo, R. J., et al. (2017) · Journal of Neurosurgery Pediatrics · doi:10.3171/2017.1.peds16576 · Cited by 33
Bishop, S., Matheus, M. G., Abboud, M. R., Cane, I. D., Adams, R. J., Jackson, S. M., & Kalpatthi, R. V. (2011) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2011.06.002 · Cited by 33
Casella, J. F., Adams, R. J., Brambilla, D. J., Strouse, J. J., Maier, P., Dlugash, R., Avadhani, R., Vermillion, K. K., Tonascia, J., Voeks, J. H., et al. (2018) · Clinical Trials · doi:10.1177/1740774518807160 · Cited by 32
Metadata
- Authors
- The Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators
- Affiliations
- Augusta University (US)
- Corresponding author
- The Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-12-29
- Volume
- 353
- Issue
- 26
- Pages
- 2769-2778
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1498156640
- Cited by
- 635
- References
- 27
- Citations by year
- 2026: 23 · 2025: 12 · 2024: 31 · 2023: 22 · 2022: 29 · 2021: 27 · 2020: 34 · 2019: 25 · 2018: 35 · 2017: 37 · 2016: 43 · 2015: 25 · 2014: 32 · 2013: 32 · 2012: 45
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (U01HL052193, U01HL052016)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Keywords
- sickle cell disease, stroke prevention, prophylactic transfusion, transcranial Doppler screening, cerebral blood flow velocity, children
- MeSH terms
- Adolescent, Adult, Anemia, Sickle Cell, Blood Flow Velocity, Blood Transfusion, Brain, Child, Female, Humans, Magnetic Resonance Imaging, Male, Risk, Chelation Therapy, Ultrasonography, Doppler, Transcranial, Stroke, Middle Cerebral Artery, Withholding Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.